Get started
Author

Mireia Melé

Observed names: M Melé, M Melé, M. Mele, M. Melé, Mireia Mele, Mireia Melé Olivé
Observed institutions: Hospital de Sant Pau, Hospital Universitari Arnau de Vilanova, Research Institute Hospital 12 de Octubre, Hospital Son Llatzer, Hospital Clínico Universitario de Valencia, Consorcio Hospitalario Provincial de Castellón, Hospital Universitario 12 De Octubre, Institut de Recerca Biomèdica Catalunya Sud, Institut Català d'Oncologia, Hospital Clínic de Barcelona, Donostiako Unibertsitate Ospitalea, Hospital Universitari Sant Joan de Reus, Hospital Universitario Ramón y Cajal, GEICAM – Spanish Breast Cancer Group, Universitat Rovira i Virgili
ORCID: 0000-0002-3408-8018
Observed ORCID: 0000-0002-3408-8018
OpenAlex ID: A5077308675
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
2021 · Sibylle Loibl, Frederik Marmé, et al. · Journal of Clinical Oncology · 349
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
2019 · T. Bachelot, E. Ciruelos, et al. · Annals of Oncology · 119
PDF
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
2020 · Eva Ciruelos, Patricia Villagrasa, et al. · Clinical Cancer Research · 118
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study
2015 · Miguel J. Gil-Gil, M. Bellet, et al. · Breast Cancer Research and Treatment · 55
Fatal pneumonitis induced by oxaliplatin
2008 · Sara Arévalo Lobera, Naiara Sagastibeltza Mariñelarena, et al. · Clinical & Translational Oncology · 28
Abstract PD3-03: SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer
2019 · E Ciruelos, P Villagrasa, et al. · Cancer Research · 18
Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B
2021 · Sibylle Loibl, Frederik Marmé, et al. · Cancer Research · 17
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
2021 · Miguel J. Gil-Gil, Meritxell Bellet, et al. · Frontiers in Oncology · 14
PDF
In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample
2016 · Marta Rodríguez-Balada, Bàrbara Roig, et al. · Cancer Genetics · 13
PDF
Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients
2019 · Marta Rodríguez-Balada, Bàrbara Roig, et al. · Clinical Biochemistry · 12
PDF
Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.
2024 · Eva Ciruelos, Tomás Pascual, et al. · Journal of Clinical Oncology · 10
Effects of radiotherapy on plasma energy metabolites in patients with breast cancer who received neoadjuvant chemotherapy
2019 · M. Arenas, S. Fernández-Arroyo, et al. · Clinical & Translational Oncology · 10
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.
2023 · Nicholas C. Turner, Frederik Marmé, et al. · Journal of Clinical Oncology · 9
PDF
Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients
2018 · M. Rodríguez-Balada, B. Roig, et al. · Clinical & Translational Oncology · 8
Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial
2018 · E Ciruelos, P Villagrasa, et al. · Cancer Research · 7
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
2025 · T. Pascual, G. Villacampa, et al. · ESMO Open · 6
123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
2021 · P. Schmid, F.J. Salvador Bofill, et al. · Annals of Oncology · 6
PDF
A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).
2018 · Juan De La Haba, Angel Guerrero-Zotano, et al. · Journal of Clinical Oncology · 6
SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer
2017 · P. Villagrasa Gonzalez, A. Prat, et al. · Annals of Oncology · 6
Opportunistic genetic screening increases the diagnostic yield and is medically valuable for care of patients and their relatives with hereditary cancer
2023 · Sara Fernández-Castillejo, Bàrbara Roig, et al. · Journal of Medical Genetics · 4
PDF
Deterioro cognitivo inducido por los tratamientos oncológicos sistémicos en el cáncer de mama no metastático: revisión de estudios
2009 · Agustina Sirgo, Beatriz Rubio, et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 4
Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).
2023 · Juan De La Haba, Antonio Anton, et al. · Journal of Clinical Oncology · 3
130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype
2021 · E.M. Ciruelos, A.A. Garcia, et al. · Annals of Oncology · 3
Abstract OT2-02-06: Palbociclib in combination with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A multi-center, randomized, open-label, phase II trial
2020 · Eva Ciruelos, Patricia Villagrasa, et al. · Cancer Research · 3
SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer.
2025 · Eva Maria Ciruelos, Tomás Pascual, et al. · Journal of Clinical Oncology · 1
Works count: 35
Citation count: 829
H-index: 10
I10-index: 12
Year
Topic
Type